Orthocell (ASX:OCC) received regulatory approval from the Brazilian Health Regulatory Agency for its Striate+ dental membrane for guided bone and tissue regeneration applications, according to a Wednesday filing with the Australian bourse.
The company is working with BioHorizons, its global marketing and distribution partner, to launch the product and expects commercial distribution in the fourth quarter of the year, the filing said.
Shares rose past 2% in morning trade Wednesday.